ALNOV:EPA
Novacyt SA
€0.44
0.00%
(0.00) 1D
Nov 19, 10:12:54 AM GMT+1 · EUR
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for ALNOV...
Open
€0.44
High
€0.44
Low
€0.44
Mkt. cap
32.30M
Avg. vol.
136.90K
Volume
10.90K
52-wk high
€1.04
52-wk low
€0.29
EPS
-€0.38
Shares outstanding
72.59M
No. of employees
228
Open
€0.44
High
€0.44
Low
€0.44
Mkt. cap
32.30M
Avg. vol.
136.90K
Volume
10.90K
52-wk high
€1.04
52-wk low
€0.29
EPS
-€0.38
Shares outstanding
72.59M
No. of employees
228
News stories
From web sources and news partners
BigGo Finance
·
4 hours ago
UBS Sets S&P 500 Target of 8,200 by End-2027, Implying Roughly 12% Upside, But Cuts Rating to Neutral
FOREX.com
·
4 hours ago
S&P 500 Grasps At Support as Surging Hike Odds, Treasury Yields Threaten Larger Turn
TradingView
·
3 hours ago
Stock Market: Will S&P 500 Open Up or Down Today?
Traders Union
·
7 hours ago
S&P 500 dips below 200-day average after long streak, Ryan Detrick notes
Profile
Novacyt Group is an Anglo-French biotechnology group focused on clinical diagnostics, with offices in Camberley, Surrey, United Kingdom and Vélizy-Villacoublay, France. The company produces in vitro and molecular diagnostic tests, supplying assays and reagents worldwide. Its business units include Primerdesign, Microgen Bioproducts and Lab21 Healthcare.
In January 2020 the company announced that its molecular diagnostics division, Primerdesign, had launched a molecular test for the 2019 strain of SARSr-CoV. The test was approved as eligible for procurement under the World Health Organization's Emergency Use Listing process in April 2020, meaning that the test could be supplied by the United Nations and other procurement agencies supporting the COVID-19 response. In the same month Novacyt announced a collaboration with AstraZeneca, GlaxoSmithKline and the University of Cambridge to support the UK in its COVID-19 national screening programme at a new testing laboratory at the university's Anne McLaren laboratory. Wikipedia
About Novacyt SA
CEODavid Allmond
Employees228
FoundedJul 3, 2006
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websitenovacyt.com